RxDoctor Payments Data

Emmanuel During, MD

Neurology · New York, NYNPI 1104110212

Payments from drug & device makers

$482,106in general payments, 2019–2025

Across 6 payments — averaging $80,351 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Jazz Pharmaceuticals Inc.$481K
  • Sanofi$1K
$18,076in research payments, 2019–2025

Across 33 payments — averaging $547.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$12K
  • Sanofi$5K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K

What the payments were for

  • Speaking & faculty fees$1,25088%
  • Food & beverage$17612%

General payments by program year

19
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Jazz Pharmaceuticals Inc.5$480,856
Sanofi1$1,250

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$482,106 in reported general payments places this provider in the 90th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$61,072
Medicare patients
180
Services billed
678

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelsomraSuvorexant50$21,352
NeuproRotigotine17$14,435
DayvigoLemborexant20$6,370
Rivastigmine27$3,797
Gabapentin44$604
Pregabalin19$366
Trazodone Hcl48$221
Pramipexole DihydrochloridePramipexole Di-Hcl11$79
Clonazepam22$62
Zolpidem Tartrate14$57

Paid to pharmacies, not to this prescriber.

Other neurology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →